Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is D1000 Varejo Farma Participacoes Debt-to-EBITDA?
D1000 Varejo Farma ParticipacoesBSP:DMVF3 -1.35%80 Debt-to-EBITDA is 3.73 as of Mar. 2026, which is 54% above its 10-year median of 2.42. GuruFocus rates BSP:DMVF3 with a GF Score™ of 80/100 and a GF Value™ of R$8.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 477 Healthcare Providers & Services companies, D1000 Varejo Farma Participacoes ranks worse than 50.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for D1000 Varejo Farma Participacoes's Debt-to-EBITDA or its related term are showing as below:
BSP:DMVF3'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -19.72 Med: 2.42 Max: 5.73
Current: 2.3
During the past 9 years, the highest Debt-to-EBITDA Ratio of D1000 Varejo Farma Participacoes was 5.73. The lowest was -19.72. And the median was 2.42.
BSP:DMVF3's Debt-to-EBITDA is ranked worse than 50.52% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs BSP:DMVF3: 2.30
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
D1000 Varejo Farma Participacoes Debt-to-EBITDA Related Terms
D1000 Varejo Farma Participacoes Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, D1000 Varejo Farma Participacoes's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D1000 Varejo Farma Participacoes Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, D1000 Varejo Farma Participacoes's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where D1000 Varejo Farma Participacoes's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
D1000 Varejo Farma Participacoes (BSP:DMVF3) has a Debt-to-EBITDA of 3.73 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on D1000 Varejo Farma Participacoes. This is 54% above median its historical median of 2.42. According to the industry distribution chart, D1000 Varejo Farma Participacoes ranks #241 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 50.5%.
Is D1000 Varejo Farma Participacoes' Debt-to-EBITDA too high?
D1000 Varejo Farma Participacoes' current Debt-to-EBITDA of 3.73 is 54% above median its 10-year median of 2.42. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. D1000 Varejo Farma Participacoes' value of 3.73 is 68% above this industry median. Based on the distribution chart, D1000 Varejo Farma Participacoes ranks #241 out of 477 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, D1000 Varejo Farma Participacoes has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does D1000 Varejo Farma Participacoes' Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, D1000 Varejo Farma Participacoes ranks #241 out of 477 companies for Debt-to-EBITDA. This places D1000 Varejo Farma Participacoes in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. D1000 Varejo Farma Participacoes' value of 3.73 is 68% above this benchmark. While the company's 10-year median is 2.42 vs. the industry median of 2.22, D1000 Varejo Farma Participacoes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D1000 Varejo Farma Participacoes's current Debt-to-EBITDA of 3.73 is 68% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on D1000 Varejo Farma Participacoes. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D1000 Varejo Farma Participacoes's current Debt-to-EBITDA is 3.73, which is 54% above median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D1000 Varejo Farma Participacoes stock overvalued right now?
Based on GuruFocus' analysis, D1000 Varejo Farma Participacoes (BSP:DMVF3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.14, compared to a current price of R$6.58 — trading 19.2% below its estimated fair value. The current Debt-to-EBITDA is 3.73, which is 54% above median its 10-year median of 2.42 and 68% above the Healthcare Providers & Services industry median of 2.22. D1000 Varejo Farma Participacoes' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For D1000 Varejo Farma Participacoes (BSP:DMVF3), the current Debt-to-EBITDA is 3.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D1000 Varejo Farma Participacoes (BSP:DMVF3) Overvalued in 2026?
Based on GuruFocus' analysis, D1000 Varejo Farma Participacoes stock appears to be undervalued.
The current stock price of R$6.58 is trading 19.2% below its estimated GF Value™ of R$8.14.
GuruFocus considers D1000 Varejo Farma Participacoes to be Modestly Undervalued.
Key valuation signals for BSP:DMVF3:
Debt-to-EBITDA: 3.73 (54% above median its 10-year median of 2.42)
GF Value™: R$8.14 vs. price of R$6.58 (19.2% below fair value)
Industry Position: 68% above the Healthcare Providers & Services median (#241 of 477)
No single metric tells the full story. See the BSP:DMVF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D1000 Varejo Farma Participacoes Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DMVF3 has been successfully added to your 
